Role of serologic and molecular diagnostic assays in identification and management of hepatitis c virus infection

Journal of Clinical Microbiology

Volumn 54, Issue 2, 2016, Pages 265-273

  Cloherty, Gavin ^a   Talal, Andrew ^b   Coller, Kelly ^a   Steinhart, Corklin ^c   Hackett, John ^a   Dawson, George ^a   Rockstroh, Juergen ^d   Feld, Jordan ^e  

^a ABBOTT DIAGNOSTICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VIIV HEALTHCARE   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DACLATASVIR; INTERFERON; LEDIPASVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; VIRUS ANTIGEN;

ACUTE HEPATITIS C; BLOOD TRANSFUSION; CHRONIC HEPATITIS C; DRUG EFFICACY; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MOLECULAR DIAGNOSIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEROLOGY; TREATMENT PLANNING; VASCULARIZATION; VIRUS IDENTIFICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ACUTE DISEASE; ANTIVIRAL RESISTANCE; CLASSIFICATION; DISEASE MANAGEMENT; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; IMMUNOLOGY; MEDICATION COMPLIANCE; MICROBIAL SENSITIVITY TEST; TREATMENT OUTCOME; VIROLOGY;

ACUTE DISEASE; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; RNA, VIRAL; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 84956612958     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02407-15     Document Type: Review

References (35)

1. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. 2008. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 47:1128-1135.
2. Global Burden of Hepatitis C Working Group. 2004. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44:20-29. http://dx.doi.org/10.1177/0091270003258669.
3. Grady GF, Chalmers TC. 1964. Risk of post-Transfusion viral hepatitis. N Engl JMed271:337-342. http://dx.doi.org/10.1056/NEJM196408132710702.
4. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ. 1970. Post-Transfusion hepatitis after open-heart operations. Incidence after administration of blood from commercial and volunteer donor populations. JAMA 211:261-265.
5. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, Schmidt PJ. 1972. Post-Transfusion hepatitis after exclusion of commercial hepatitis B surface antigen positive donors. Ann Intern Med 77: 691-699. http://dx.doi.org/10.7326/0003-4819-77-5-691.
6. Couroucé AM, Le Marrec N, Girault A, Ducamp S, Simon N. 1994. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second and third generation anti-HCV assays. Transfusion 34:790-795. http://dx.doi.org/10.1046/j.1537-2995.1994.34994378281.x.
7. Selvarajah S, Busch MP. 2012. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther 17:1423-1429. http://dx.doi.org/10.3851/IMP2459.
8. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. 2008. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. Am J Epidemiol 168:1099-1109. http://dx.doi.org/10.1093/aje/kwn237.
9. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. 2011. Changes in blood-borne infection risk among injection drug users. J Infect Dis 203:587-594. http://dx.doi.org/10.1093/infdis/jiq112.
10. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, Church DR, Barton K, Fisher C, Macomber K, Stanley M, Guilfoyle SM, Sweet K, Liu S, Iqbal K, Tohme R, Sharapov U, Kupronis BA, Ward JW, Holmberg SD. 2014. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 59:1411-1419. http://dx.doi.org/10.1093/cid/ciu643.
11. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD; Chronic Hepatitis Cohort Study Investigators. 2012. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 55:1047-1055. http://dx.doi.org/10.1093/cid/cis616.
12. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. 2012. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 157:817-822. http://dx.doi.org/10.7326/0003-4819-157-9-201211060-00529.
13. Micallef JM, Kaldor JM, Dore GJ. 2006. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 13:34-41. http://dx.doi.org/10.1111/j.1365-2893.2005.00651.x.
14. Chevaliez S. 2011. Virological tools to diagnose and monitor hepatitis C infection. Clin Microbiol Infect 17:116-121. http://dx.doi.org/10.1111/j.1469-0691.2010.03418.x.
15. Hullegie SJ, Arends JE, Rijnders BJ, Irving WL, Salmon D, Prins M, Wensing AM, Klenerman P, Leblebicioglu H, Boesecke C, Rockstroh JK, Hoepelman AI. 2015. Current knowledge and future perspectives on acute hepatitis C infection. Clin Microbiol Infect 21:797.e9-797.e17. http://dx.doi.org/10.1016/j.cmi.2015.03.026.
16. Urbanus AT, Van De Laar TJ, Geskus R, Vanhommerig JW, Van Rooijen MS, Schinkel J, Heijman T, Coutinho RA, Prins M. 2014. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS 28:781-790. http://dx.doi.org/10.1097/QAD.0000000000000126.
17. Pollicita M, Cento V, Paba P, Perno CF, Ciotti M. 2013. Nucleotide polymorphisms in the 5=-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. J Virol Methods 193:205-208. http://dx.doi.org/10.1016/j.jviromet.2013.06.002.
18. Larrat S, Poveda JD, Coudret C, Fusillier K, Magnat N, Signori-Schmuck A, Thibault V, Morand P. 2013. Sequencing assays for failed genotyping with the Versant hepatitis C virus genotype assay (LiPA), version 20. J Clin Microbiol 51:2815-2821. http://dx.doi.org/10.1128/JCM.00586-13.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759.
20. Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio G, Sarrazin C. 2014. HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther 19:559-567. http://dx.doi.org/10.3851/IMP2760.
21. Sarrazin C, Wedemeyer H, Cloherty G, Cohen DE, Chevaliez S, Herman C, Bernstein B, Pawlotsky JM. 2015. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods 214:29-32. http://dx.doi.org/10.1016/j.jviromet.2014.11.027.
22. Lawitz E, Poordad FF, Pang SP, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. 2014. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383(9916):515-523. http://dx.doi.org/10.1016/S0140-6736(13)62121-2.
23. Cento V, Chevaliez S, Perno CF. 2015. Resistance to direct-Acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS 10(5): 381-389. http://dx.doi.org/10.1097/COH.0000000000000177.
24. Kao J-H, Heo J, Yoffe B, Sievert W, Jacobson I, Bessone F, Peng C-Y, Roberts S, Yoon KT, Kopit J, Linaberry M, Noviello S, Hughes E, Manns M. 2014. Efficacy and safety of daclatasvir in combination with asunaprevir (DCV-ASV) in cirrhotic and non-cirrhotic patients with HCVgenotype 1b: results of the Hallmark dual study. J Hepatol 60(Suppl): S527-S528. http://dx.doi.org/10.1016/S0168-8278(14)61467-7.
25. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 57:221-229. http://dx.doi.org/10.1093/cid/cit226.
26. Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. 2014. Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comput Biol 10:e1003772. http://dx.doi.org/10.1371/journal.pcbi.1003772.
27. Dvory-Sobolemail H, Wyles D, Ouyang W, Chodavarapu K, McNally J, Cheng W, Shafran S, Mangia A, Schwabe C, Miller MD, Mo H. 2015. Long-Term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 62(Suppl 2):S221. http://dx.doi.org/10.1016/S0168-8278(15)30073-8.
28. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. 2015. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomized, open-label phase 2 trial. Lancet 385:1087-1097. http://dx.doi.org/10.1016/S0140-6736(14) 61793-1.
29. Vermehren J, Maasoumy B, Chevaliez S, Feld JJ, Cloherty G, Pawlotsky J-M, Sarrazin C, Wedemeyer H. 2015. Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCV RNA assays. J Hepatol 62(Suppl 2):S600. http://dx.doi.org/10.1016/S0168-8278(15)30938-7.
30. Lawitz EJ, Membreno FE. 2014. Response-guided therapy in patients with genotype 1 HCV: current status and future prospects. J Gastroenterol Hepatol 29:1574-1581. http://dx.doi.org/10.1111/jgh.12632.
31. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. 2013. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 27:2551-2557. http://dx.doi.org/10.1097/QAD.0b013e32836381cc.
32. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. 2015. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. veterans. Aliment Pharmacol Ther 42:559-573. http://dx.doi.org/10.1111/apt.13300.
33. Canary LA, Klevens RM, Holmberg SD. 2015. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med 163:226-228. http://dx.doi.org/10.7326/M15-0320.
34. Churchyard GJ, Stevens WS. 2015. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: A clusterrandomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 3:e450-e457. http://dx.doi.org/10.1016/S2214-109X(15)00100-X.
35. Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, Carman WF. 2012. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol 54:106-109. http://dx.doi.org/10.1016/j.jcv.2012.02.004.